	Actif À Court Terme		Date
AbbVie	USD 29.06B	523M	2025-12
Amgen	USD 29.06B	1.17B	2025-12
Anika Therapeutics	USD 101.59M	2.27M	2025-09
Arrowhead Research	USD 1.17B	223.75M	2025-12
AstraZeneca	USD 28.72B	1.22B	2025-12
BioCryst Pharmaceuticals	USD 355.68M	42.78M	2025-09
Biogen	USD 8.97B	37.5M	2025-12
Bristol-Myers Squibb	USD 35.63B	2.41B	2025-09
Enanta Pharmaceuticals	USD 198.68M	5.65M	2025-12
Gilead Sciences	USD 19.89B	1.05B	2025-12
GlaxoSmithKline	GBP 17.51B	332M	2025-12
Halozyme Therapeutics	USD 825.21M	503.54M	2025-12
Heron Therapeutics	USD 229.4M	18.48M	2025-09
Immunic	USD 39.27M	20.57M	2025-09
Incyte	USD 5.02B	746.01M	2025-12
Insmed	USD 1.79B	137.6M	2025-12
Ionis Pharmaceuticals	USD 2.99B	471.01M	2025-12
J&J	USD 55.62B	1.01B	2025-12
Karyopharm Therapeutics	USD 89.75M	8.12M	2025-09
Ligand Pharmaceuticals	USD 832.27M	78.35M	2025-12
Merck	USD 47.56B	10.49B	2025-09
Neurocrine Biosciences	USD 2.52B	364.3M	2025-12
Novartis	USD 28.2B	2.26B	2025-09
Novavax	USD 974.59M	55.08M	2025-09
Pfizer	USD 46.92B	3.22B	2025-09
PTC Therapeutics	USD 2.27B	266.14M	2025-12
Roche Holding	CHF 38.73B	3.03B	2025-12
Sarepta Therapeutics	USD 2.54B	184.37M	2025-12
Vertex Pharmaceuticals	USD 11.2B	631.4M	2025-12

Enanta Pharmaceuticals Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.